Combination Therapy in Dyslipidemia

Book Overview

​ Foreword .- Statins and bile acid resins - is there a place for such a combination?.- Statins and fibrates - should it be recommended?.- Statins and ezetimibe - doubts or bright future?.- Statins and niacin - the end of residual risk therapy?.- Statins and omega-3 fatty acids - what more do we need?.- Statins and CETP inhibitors - anacetrapib and evacetrapib - the last hope?.- Statins and mipomersen - the issue of tolerability?.- Statins and lomitapide - a suitable response for HoFH.- Statins and PCSK9 inhibitors - defining the correct patients.- Other possible drug combination for dyslipidaemia.- Statins and nutraceuticals/functional food - Could be they combined?.- Lipid lowering therapy and apheresis - indications and outcomes.- Combination of lipid lowering agents with antihypertensive drugs - a joint fight against the two most important risk factors?.- Not only dyslipidaemia therapy - the time for polypills.- Drug Evaluation: Fenofibrate + simvastatin for the treatment of dyslipidemia: When and for whom?.- Drug Evaluation: Olmesartan medoxomil + rosuvastatin for the treatment of dyslipidemia and concomitant risk factors: A chance for better compliance?.- Conclusions and Take Home Message.

• Format: Paperback
• Language: English
• ISBN: 3319367218
• ISBN13: 9783319367217
• Release Date: October 2016
• Publisher: Adis
• Length: 205 Pages
• Weight: 0.68 lbs.
• Dimensions: 0.5" x 6.1" x 9.2"